Astellas

-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX- -CytomX-retained US co-commercialization and…

Newark, New Castle, USA, Jan. 20, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, “Immunology Market by Drug Class (Monoclonal antibody (mAb), Polyclonal…

DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing…

Pune, Oct. 10, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global secondary hyperparathyroidism treatment market is expected to clock at…

TOKYO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verizon Business has been selected to manage Astellas Pharma Inc’s (Astellas) global network infrastructure. The network transformation will…

- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for patients who do not respond to existing cancer…

TOKYO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno,…

TOKYO, June 25, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno,…